Swiss approve new breast cancer drug

, Comments 0 comments BERN, SWITZERLAND - Swissmedic, which oversees drug approvals in Switzerland, has accepted a new treatment for breast cancer, Eribulin Halaven. The drug was developed by Japanese research firm Eisai. It was approved 18 May for use in Switzerland as a monotherapy treatment of patients with locally advanced and metastatic breast carcinoma with progression after prior ...Swiss approve new breast cancer drug ©, Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported.

0 Comments To This Article